Two cancer drug trials put on hold after patients died, companies say | CNN

  • 📰 cnni
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 59%

Canada News News

Canada Canada Latest News,Canada Canada Headlines

Two clinical trials have been paused within the past two days because six participants – including one child – have died, according to reports by the drug companies.

The two trials were unrelated: They were in different stages and testing therapies. But both were testing new cancer treatments. One was testing a treatment for a blood cancer called acute myeloid leukemia, or AML, and the other was testing a new agent for ovarian cancer. Deaths in clinical trials are thought to be rare.

“The safety of every patient who participates in our studies or is treated with our therapies is the utmost priority for us, and we are in communication with FDA while we assess the data surrounding this SAE [serious adverse event], and the potential next steps for the study,” said Dr. Steve Bernstein, chief medical officer 2seventy bio, in a news release. The second study, on ovarian cancer, was in phase three – typically the final stage before a company presents a drug for FDA approval.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 326. in CA
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Canada Canada Latest News, Canada Canada Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Sam Bankman-Fried's trial to be split up as attorneys challenge some counts | CNN BusinessFTX founder Sam Bankman-Fried will have his criminal trial split into two separate proceedings, a judge ruled Thursday, granting a request from prosecutors who worried that five of the 13 charges could be held up by a Bahamian court’s review.
Source: CNN - 🏆 4. / 95 Read more »